<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01358903</url>
  </required_header>
  <id_info>
    <org_study_id>BP25385</org_study_id>
    <secondary_id>2010-021168-13</secondary_id>
    <nct_id>NCT01358903</nct_id>
  </id_info>
  <brief_title>A Study of RO5429083 in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors</brief_title>
  <official_title>Open-Label Multicenter 2-Arm Phase I Study of RO5429083 With Dose-Escalation and Extension Cohorts, and Imaging Cohorts With RO5429083 and 89Zr-labeled RO5429083, in Patients With Metastatic and/or Locally Advanced, CD44-Expressing, Malignant Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This open-label 2-arm study will assess the pharmacokinetics, pharmacodynamics, safety and
      efficacy of RO5429083 in patients with metastatic and/or locally advanced CD44-expressing
      malignant solid tumors. In Part A, cohorts of patients will receive RO5429083 intravenously
      at escalating doses. In Part B, patients will receive 89Zr-labelled RO5429083 in Cycles 1
      and/or 2, followed by RO5429083. For all patients there will be an option to continue
      treatment with RO5429083 until disease progression or unacceptable toxicity occurs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Arm A: Safety (Incidence of adverse events related to study drug)</measure>
    <time_frame>Until disease progression or unacceptable toxicity (approximately 2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm A: Maximum tolerated dose of RO5429083</measure>
    <time_frame>Until disease progression or unacceptable toxicity (approximately 2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm A: Tumor Growth Control Rate</measure>
    <time_frame>Until disease progression or unacceptable toxicity (approximately 2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm B: Tissue distribution of RO5429083 assessed by positron emission tomography (PET)</measure>
    <time_frame>Until disease progression or unacceptable toxicity (approximately 2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm A: Pharmacokinetics (serum levels of RO5429083)</measure>
    <time_frame>Until disease progression or unacceptable toxicity (approximately 2 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arm A: Recommended dose of RO5429083 for the extension cohort</measure>
    <time_frame>Until disease progression or unacceptable toxicity (approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm A: Anti-tumor activity of RO5429083</measure>
    <time_frame>Until disease progression or unacceptable toxicity (approximately 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm B: Target saturation of 89Zr-labelled RO5429083</measure>
    <time_frame>Until disease progression or unacceptable toxicity (approximately 2 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5429083</intervention_name>
    <description>Cohorts receiving multiple escalating doses iv</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RO5429083</intervention_name>
    <description>Cohorts receiving 89Zr-labelled RO5429083 plus RO5429083, followed by RO5429083 until disease progression</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients, &gt;/= 18 years of age

          -  Metastatic and/or locally advanced malignant CD44-expressing solid tumors

          -  Patients with disease progression on standard therapy, or have tumors that are not
             curable by standard therapy

          -  Life expectancy of over 12 weeks

        Exclusion Criteria:

          -  Concurrent therapy with any other investigational drug

          -  Known or suspected CNS metastases including leptomeningeal metastases

          -  Active bleeding, bleeding diathesis or history of coagulation disorder

          -  Uncontrolled diabetes mellitus

          -  Active or uncontrolled infections

          -  Patients with HIV infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris</city>
        <zip>75231</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 20, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2011</study_first_posted>
  <last_update_submitted>November 1, 2016</last_update_submitted>
  <last_update_submitted_qc>November 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

